Form 4: Immunovant COO Sells Shares for Tax Obligations

Immunovant's Chief Operating Officer, Melanie Gloria, sold 12,626 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Melanie Gloria, Chief Operating Officer of Immunovant, Inc. (IMVT), reported the sale of common stock.
• On November 20, 2025, a total of 12,626 shares were sold in two separate transactions.
• The first transaction involved 10,251 shares sold at a weighted average price of $23.54 per share, with prices ranging from $22.93 to $23.91.
• The second transaction involved 2,375 shares sold at a weighted average price of $23.97 per share, with prices ranging from $23.93 to $24.05.
• These sales were executed to cover tax withholding obligations associated with the vesting and settlement of 27,489 restricted stock units (RSUs) that vested on November 18, 2025.
• The sale was mandated by Immunovant's policy requiring a 'sell to cover' transaction for tax obligations and was not a discretionary transaction by Ms. Gloria.
• Following these transactions, Ms. Gloria beneficially owns 173,511 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a standard event for executives receiving equity compensation and does not reflect a positive or negative outlook on the company's performance or future prospects.

Positives

• The transaction is a routine 'sell to cover' for tax withholding, indicating a standard compensation event rather than a discretionary sale reflecting a negative outlook.

Negatives

• The sale of shares, while non-discretionary, reduces the Chief Operating Officer's direct beneficial ownership in the company.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing details an individual insider transaction, which is specific to the reporting person and company, and does not directly relate to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine 'sell to cover' for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's stock price, as it does not signal a discretionary change in management's confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' to satisfy tax obligations arising from RSU vesting. This is a routine event for executives and does not indicate a change in management's confidence in the company's future or its operational performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Immunovant, IMVT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Melanie Gloria, Chief Operating Officer